BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 32435023)

  • 21. Use of Isoquercetin in the Treatment of Prurigo Nodularis.
    Pennesi CM; Neely J; Marks AG; Basak SA
    J Drugs Dermatol; 2017 Nov; 16(11):1156-1158. PubMed ID: 29141065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful Treatment of Prurigo Nodularis by Dupilumab: Report of 24 Patients.
    Gao Z; Dou Y; Zhao P; Wang CJ; Zhang J
    Dermatology; 2023; 239(4):658-663. PubMed ID: 37011607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of dupilumab in prurigo nodularis in elderly patient.
    Giura MT; Viola R; Fierro MT; Ribero S; Ortoncelli M
    Dermatol Ther; 2020 Jan; 33(1):e13201. PubMed ID: 31856368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prurigo nodularis in a 9-year-old girl.
    Amer A; Fischer H
    Clin Pediatr (Phila); 2009 Jan; 48(1):93-5. PubMed ID: 18648078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.
    Hendricks AJ; Yosipovitch G; Shi VY
    J Dermatolog Treat; 2021 Feb; 32(1):19-28. PubMed ID: 31693426
    [No Abstract]   [Full Text] [Related]  

  • 26. [Prurigo nodularis: its association with dermatoses and systemic disorders].
    Mettang T; Vonend A; Raap U
    Hautarzt; 2014 Aug; 65(8):697-703. PubMed ID: 25113328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
    Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
    van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.
    Patruno C; Napolitano M; Argenziano G; Peris K; Ortoncelli M; Girolomoni G; Offidani A; Ferrucci SM; Amoruso GF; Rossi M; Stingeni L; Malara G; Grieco T; Foti C; Gattoni M; Loi C; Iannone M; Talamonti M; Stinco G; Rongioletti F; Pigatto PD; Cristaudo A; Nettis E; Corazza M; Guarneri F; Amerio P; Esposito M; Belloni Fortina A; Potenza C; Fabbrocini G;
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):958-964. PubMed ID: 33332697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Learning from nemolizumab: A promising therapy for prurigo nodularis.
    Kim BS
    J Allergy Clin Immunol; 2024 Jun; 153(6):1548-1549. PubMed ID: 38460679
    [No Abstract]   [Full Text] [Related]  

  • 31. Dupilumab for the Treatment of Prurigo Nodularis.
    Alkhaleefa A; Woo TE; Parsons L
    Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab as promising treatment for prurigo nodularis: current evidences.
    Toffoli L; Farinazzo E; Zelin E; Agozzino M; Dianzani C; Di Meo N; Nan K; Zalaudek I; Conforti C
    J Dermatolog Treat; 2022 May; 33(3):1306-1311. PubMed ID: 33588666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intractable prurigo nodularis successfully treated with combination therapy with a newly developed excimer laser and topical steroids.
    Nakashima C; Tanizaki H; Otsuka A; Miyachi Y; Kabashima K
    Dermatol Online J; 2014 Jun; 20(6):. PubMed ID: 24945654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dupilumab Treatment for Prurigo Nodularis and Pruritis.
    Tanis R; Ferenczi K; Payette M
    J Drugs Dermatol; 2019 Sep; 18(9):940-942. PubMed ID: 31524352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Case of Linear Exacerbation of Atopic Dermatitis with Secondary Prurigo Nodularis.
    Kang HJ; Kim HJ; Han JH; Bang CH; Kim TY
    Ann Dermatol; 2022 Aug; 34(4):297-300. PubMed ID: 35948333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series.
    Siepmann D; Luger TA; Ständer S
    J Dtsch Dermatol Ges; 2008 Nov; 6(11):941-6. PubMed ID: 18445069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prurigo pigmentosa associated with an atopic diathesis in a 13-year-old girl.
    Cota C; Donati P; Amantea A
    Pediatr Dermatol; 2007; 24(3):277-9. PubMed ID: 17542880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life.
    Richter C; Hafner J; Schuermann M; Tanadini M; Trisconi N; Schmid-Grendelmeier P; Kündig T; Nägeli M; Brüggen MC; Guillet C
    Dermatology; 2023; 239(5):811-817. PubMed ID: 37369187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of dupilumab for chronic prurigo in elderly patients with atopic dermatitis.
    Mitsuyama S; Higuchi T
    An Bras Dermatol; 2023; 98(1):86-89. PubMed ID: 36376117
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.